Aceto Consolidates Acquisition of Six Manufacturers, Strengthening Its Unique Hybrid Model that Provides Major Supply Chain Benefits to Customers
Summary
PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, today reported it has consolidated and integrated its six manufacturing-related acquisitions to achieve a hybrid manufacturing/distribution model providing key benefits to its customers in high-growth end markets including pharmaceuticals, biopharmaceuticals, vaccines, nutraceuticals, agriculture, cosmetics and specialty chemicals. The company’s expert procurement teams, which are strategically located in centers of excellence in key regions across Asia, Europe and North America, represent a major resource for Aceto’s customers. This allows them to more rapidly develop and commercialize innovative products while assuring a diversified, flexible and dependable supply chain, whose critical importance has been so dramatically highlighted by the ongoing pandemic. We intend to continue to invest in advanced systems and additional targeted acquisitions to further integrate and augment our operations and provide ever greater capabilities and value to our diverse and growing customer base.” Prior to the Covid-19 pandemic, Aceto had recognized the growing demand in the pharmaceutical and biopharmaceutical sectors for high-quality critical GMP excipients and raw materials, and as part of its growth strategy it expanded its manufacturing footprint by acquiring six companies in less than 18 months, increasing its global R&D and GMP manufacturing capabilities. Aceto’s global operations, including a significant presence on the ground in China, India, Europe and North America, enable the company’s deep worldwide sourcing and regulatory capabilities.